{ "id": "SQ-LIP-000035", "question": "Do hormonal factors (puberty, pregnancy, menopause, estrogen) trigger or influence lipedema onset?", "question_pt": "Fatores hormonais (puberdade, gravidez, menopausa, estrogênio) desencadeiam ou influenciam o início do lipedema?", "phrasings": [], "phrasings_pt": [], "knowledge_state": "emerging", "tags": [ "Etiology", "Genetics", "Hormones" ], "keywords": [ "hormones", "estrogen", "puberty", "lipedema onset" ], "current_answer": "Based on currently indexed evidence, hormonal factors are consistently described as associated with lipedema onset and exacerbation, but the evidence is overwhelmingly observational, descriptive, and mechanistic rather than causal. CONVERGENT TEMPORAL ASSOCIATION: Multiple cross-sectional surveys, case series, and reviews report that lipedema onset or worsening clusters at female reproductive hormonal transitions — puberty (reported in ~32–72% of cohorts; 55% in one case series), pregnancy (~9.5–63%), and menopause (~2–68% reporting worsening; ~20% of cases first identified at menopause) — and that the condition occurs almost exclusively in women (SCR-LIP-000004, 000110, 000141, 000153, 000219, 000222, 000223, 000224, 000229, 000230, 000313). Hormonal contraceptive use is associated with self-reported symptom worsening in one low-quality cross-sectional study (58.8% of users; SCR-LIP-000039). MECHANISTIC HYPOTHESES: Several narrative/systematic reviews propose estrogen-regulated mechanisms — an altered estrogen receptor pattern (reduced ERα / increased ERβ) in gluteofemoral adipose tissue, increased local aromatase (CYP19A1) and intracrine estradiol production, and progesterone-pathway dysregulation (SCR-LIP-000109, 000110, 000154, 000221, 000225, 000229, 000230, 000232, 000314). GENETIC-HORMONAL OVERLAP: Familial aggregation (15–89% across studies) and variants in hormone-metabolism genes (AKR1C1/AKR1C2 in progesterone metabolism; PIT1; GWAS loci genetically correlated with leptin and age at menopause) link hereditary and hormonal pathways (SCR-LIP-000157, 000219, 000220, 000223, 000224, 000226, 000231, 000315). IMPORTANT COUNTERWEIGHT: The single HIGH-quality PRISMA systematic review/meta-analysis found NO significant difference in circulating testosterone or estradiol between lipedema patients and controls, and concluded the fundamental etiology remains uncertain (SCR-LIP-000111). Thus, the hormonal association rests on timing of onset, female predominance, and tissue-level receptor/enzyme findings rather than on demonstrated systemic hormone-level abnormalities.", "current_answer_pt": "Com base nas evidências atualmente indexadas, os fatores hormonais são consistentemente descritos como associados ao início e à exacerbação do lipedema, mas as evidências são predominantemente observacionais, descritivas e mecanísticas, e não causais. ASSOCIAÇÃO TEMPORAL CONVERGENTE: Múltiplos levantamentos transversais, séries de casos e revisões relatam que o início ou a piora do lipedema se agrupam em transições hormonais reprodutivas femininas — puberdade (~32–72% das coortes; 55% em uma série de casos), gravidez (~9,5–63%) e menopausa (~2–68% relatando piora; ~20% dos casos identificados pela primeira vez na menopausa) — e que a condição ocorre quase exclusivamente em mulheres (SCR-LIP-000004, 000110, 000141, 000153, 000219, 000222, 000223, 000224, 000229, 000230, 000313). O uso de contraceptivos hormonais associa-se à piora autorrelatada dos sintomas em um estudo transversal de baixa qualidade (58,8% das usuárias; SCR-LIP-000039). HIPÓTESES MECANÍSTICAS: Várias revisões propõem mecanismos regulados por estrogênio — padrão alterado de receptores de estrogênio (ERα reduzido / ERβ aumentado) no tecido adiposo glúteo-femoral, aumento da aromatase local (CYP19A1) e produção intrácrina de estradiol, e desregulação da via da progesterona (SCR-LIP-000109, 000110, 000154, 000221, 000225, 000229, 000230, 000232, 000314). SOBREPOSIÇÃO GENÉTICO-HORMONAL: Agregação familiar (15–89%) e variantes em genes do metabolismo hormonal (AKR1C1/AKR1C2 no metabolismo da progesterona; PIT1; loci de GWAS correlacionados geneticamente com leptina e idade da menopausa) ligam as vias hereditária e hormonal (SCR-LIP-000157, 000219, 000220, 000223, 000224, 000226, 000231, 000315). CONTRAPONTO IMPORTANTE: A única revisão sistemática/meta-análise de ALTA qualidade (PRISMA) não encontrou diferença significativa nos níveis circulantes de testosterona ou estradiol entre pacientes com lipedema e controles, concluindo que a etiologia fundamental permanece incerta (SCR-LIP-000111). Assim, a associação hormonal baseia-se no momento do início, na predominância feminina e em achados teciduais de receptores/enzimas, e não em anomalias demonstradas nos níveis hormonais sistêmicos.", "bottom_line": "Lipedema onset is consistently reported to cluster around puberty, pregnancy, and menopause, and the condition occurs almost exclusively in women, supporting a real association with female hormonal transitions; tissue-level changes in estrogen receptors and related genes add biological plausibility. However, the highest-quality study found no difference in circulating estrogen or testosterone between people with lipedema and controls, no study has tested whether hormones actually cause lipedema, and it remains unknown whether hormonal shifts trigger the condition or simply unmask an inherited predisposition.", "bottom_line_pt": "O início do lipedema é consistentemente relatado em torno da puberdade, gravidez e menopausa, e a condição ocorre quase exclusivamente em mulheres, o que apoia uma associação real com as transições hormonais femininas; alterações teciduais nos receptores de estrogênio e em genes relacionados reforçam a plausibilidade biológica. No entanto, o estudo de maior qualidade não encontrou diferença nos níveis circulantes de estrogênio ou testosterona entre pessoas com lipedema e controles, nenhum estudo testou se os hormônios realmente causam a doença, e permanece incerto se as mudanças hormonais desencadeiam o lipedema ou apenas revelam uma predisposição hereditária preexistente.", "major_uncertainty": "Causality is not established: the temporal clustering at puberty/pregnancy/menopause and female predominance are consistent with hormonal influence but derive from low-grade descriptive/self-report data subject to recall and selection bias, while the highest-quality evidence (PRISMA meta-analysis) found NO difference in systemic estradiol/testosterone. Whether observed tissue-level ER/aromatase changes are causes or consequences, and whether hormones trigger onset versus merely exacerbate pre-existing predisposition, remains unresolved. No interventional or prospective data test hormonal causation.", "version": "1.1", "created": "2026-06-02", "updated": "2026-06-02", "compiled_by": { "model": "anthropic/claude-opus-4.8", "label": "Claude Opus 4.8", "date": "2026-06-02" }, "outcomes": [ { "outcome": "Onset clustering at hormonal transitions (puberty/pregnancy/menopause)", "outcome_pt": "Agrupamento do início em transições hormonais (puberdade/gravidez/menopausa)", "direction": "increased", "confidence": "low", "disease_modifying": false, "note": "Consistent across surveys/series but descriptive, self-reported, prone to recall bias.", "note_pt": "Consistente em levantamentos/séries, porém descritivo, autorrelatado e sujeito a viés de memória." }, { "outcome": "Systemic estradiol/testosterone difference vs controls", "outcome_pt": "Diferença sistêmica de estradiol/testosterona vs controles", "direction": "no_effect", "confidence": "high", "disease_modifying": false, "note": "PRISMA meta-analysis: no significant difference in plasma estradiol or testosterone.", "note_pt": "Meta-análise PRISMA: sem diferença significativa em estradiol ou testosterona plasmáticos." }, { "outcome": "Tissue-level estrogen receptor/aromatase alterations", "outcome_pt": "Alterações teciduais de receptor de estrogênio/aromatase", "direction": "mixed", "confidence": "very_low", "disease_modifying": true, "note": "Proposed ERα↓/ERβ↑ and CYP19A1↑ mechanisms; causal vs consequential role unresolved.", "note_pt": "Mecanismos propostos ERα↓/ERβ↑ e CYP19A1↑; papel causal vs consequente indefinido." }, { "outcome": "Hormonal contraceptive use and symptom worsening", "outcome_pt": "Uso de contraceptivo hormonal e piora dos sintomas", "direction": "increased", "confidence": "low", "disease_modifying": false, "note": "Single cross-sectional study; self-reported worsening; recall/selection bias.", "note_pt": "Estudo transversal único; piora autorrelatada; viés de memória/seleção." }, { "outcome": "Hormone-metabolism gene variants linking heredity and hormones", "outcome_pt": "Variantes em genes do metabolismo hormonal ligando hereditariedade e hormônios", "direction": "increased", "confidence": "low", "disease_modifying": true, "note": "AKR1C1/2, PIT1, GWAS loci correlated with leptin/menopause age; small families/suggestive signals.", "note_pt": "AKR1C1/2, PIT1, loci de GWAS correlacionados com leptina/idade da menopausa; famílias pequenas/sinais sugestivos." } ], "evidence_direction": { "supporting": 24, "contradicting": 0, "other": 1 }, "knowledge_freshness": { "pct": 79, "sources": 28, "newest": 2026, "oldest": 2010, "small_base": false, "label": "current evidence base" }, "claims": [ { "id": "SCR-LIP-000004", "role": "supporting", "statement": "Lipedema is a multifactorial disorder whose symptoms are closely linked to female hormonal transitions (puberty, pregnancy, menopause) and to chronic low-grade inflammation, on a polygenic predisposition." }, { "id": "SCR-LIP-000039", "role": "supporting", "statement": "In women with lipedema, hormonal contraceptive use is associated with self-reported symptom worsening (58.8% of users; 15.1% reporting symptom onset coinciding with contraceptive initiation)." }, { "id": "SCR-LIP-000109", "role": "supporting", "statement": "A systematic review identified four distinct pathophysiological hypotheses linking hormonal dysregulation—particularly estrogen metabolism and receptor function, growth hormone imbalance, and adipokine/leptin-related adipose stem cell alterations—to lipedema development, with possible genetic susceptibility components." }, { "id": "SCR-LIP-000110", "role": "supporting", "statement": "Lipedema is described as an estrogen-regulated polygenic disorder that manifests almost exclusively in women, with onset at hormonal transition phases (puberty, pregnancy, menopause), family aggregation in at least 16% of cases, and a pathological ERα/ERβ receptor pattern in white adipose tissue driving site-specific lipogenesis." }, { "id": "SCR-LIP-000111", "role": "context", "statement": "A systematic review of lipedema pathology found that testosterone and estradiol showed no significant difference versus controls in plasma analysis, while the condition almost exclusively affects females and its fundamental etiology remains largely uncertain despite growing molecular and histological research." }, { "id": "SCR-LIP-000153", "role": "supporting", "statement": "In a survey of 209 lipedema patients, symptom onset clustered in adolescence (mean age 16±9 years, 32.5% at ages 14-18), family history was common (affected grandmothers 35.4%, mothers 29.7%, aunts 23.0%), and 30.5% of premenopausal patients had sex-hormone imbalances, consistent with hormonal and hereditary contributions to lipedema onset." }, { "id": "SCR-LIP-000154", "role": "supporting", "statement": "This critical review proposes an integrative pathomechanism in which lipedema is an estrogen-regulated polygenetic disease, citing up to 60% of cases suggesting autosomal dominant inheritance with incomplete penetrance (Child et al., 330 relatives) and manifestation paralleling feminine hormonal changes, alongside estrogen receptor differences (decreased ERα, increased ERβ in the gluteal region) and animal models (PROX1+/-, VEGFR-3 mutants)." }, { "id": "SCR-LIP-000141", "role": "supporting", "statement": "In a Saudi cross-sectional study of 115 patients with lower-limb edema, lipedema was clinically confirmed in 71%, affected only women with mean age 38.6 years and mean BMI 30.5, with disease onset typically at ages 20-39, perceived triggers being puberty (49%), pregnancy (22%), and massive weight loss (22%), a positive family history in 46% (predominantly mothers and sisters), and 77% being previously undiagnosed." }, { "id": "SCR-LIP-000156", "role": "supporting", "statement": "A case report of idiopathic lipedema in a 62-year-old male—only the third such male case reported worldwide—notes that two of the three known male cases had associated hormonal alterations (alcoholic cirrhosis; type 1 diabetes plus alcohol abuse), and the near-exclusive female predominance is cited as suggesting a hormonal role in pathogenesis." }, { "id": "SCR-LIP-000157", "role": "supporting", "statement": "This systematic review reports familial incidence of lipedema in 15% of first-degree female relatives consistent with X-linked dominant or autosomal dominant inheritance with incomplete penetrance, identifies an AKR1C1 missense variant (a gene involved in progesterone metabolism) as the first mutated gene in a family with primary non-syndromic lipedema, and notes hormonal/progesterone-pathway involvement." }, { "id": "SCR-LIP-000219", "role": "supporting", "statement": "In a series of 67 probands, 14.9% had at least one affected first-degree relative (all affected relatives female), X-chromosome linkage analysis in the largest family excluded X-linked dominant inheritance (lod scores < -2) favoring autosomal dominant inheritance with sex limitation, and onset at puberty in 55% of probands plus near-exclusive female occurrence suggested estrogen-dependent expression." }, { "id": "SCR-LIP-000220", "role": "supporting", "statement": "This narrative review reports genetic evidence (305 candidate genes via next-generation sequencing in 162 patients; 18 GWAS risk loci including VEGFA and GRB14-COBLL1 validated in UK Biobank; monogenic AKR1C1 and PIT1 mutations affecting progesterone and growth-hormone/prolactin pathways) supporting both hereditary and hormonal influences on lipedema onset." }, { "id": "SCR-LIP-000221", "role": "supporting", "statement": "This integrative review proposes that menopause acts as a critical inflection point in lipedema progression via estrogen receptor imbalance (downregulated ERα and upregulated ERβ in affected tissue), increased local intracrine estradiol production through elevated aromatase (CYP19A1) and 17β-HSD1 with deficient 17β-HSD2, and progesterone resistance, reframing lipedema as an estrogen-dependent disorder." }, { "id": "SCR-LIP-000222", "role": "supporting", "statement": "This comparative narrative review reports that lipedema is almost exclusively found in women and typically begins during periods of hormonal change (puberty, pregnancy, menopause), and notes heritability/genetic markers as part of its genetics domain." }, { "id": "SCR-LIP-000223", "role": "supporting", "statement": "This multidisciplinary review reports that lipedema shows familial history in 30-89% of cases with polygenic GWAS findings (loci in CPE, ZNF25, ZNF33A linked to estrogen biology, plus VEGFA and GRB14-COBLL1, and an AKR1C1 missense variant) and that onset or worsening clusters at hormonal transitions—puberty (15.7-67.3%), pregnancy/lactation (9.5-63.1%), and menopause (1.9-21%)—with estradiol altering ERα/ERβ and PPAR-γ2 expression in lipedema-derived adipose stem cells." }, { "id": "SCR-LIP-000224", "role": "supporting", "statement": "In a rigorously defined UK lipedema cohort (n=130), onset was frequently associated with hormonal changes (puberty, pregnancy, menopause), and the first dedicated GWAS identified a suggestive genetic locus (rs1409440, OR_meta 2.01, P_meta 4×10⁻⁶) upstream of LHFPL6, replicated in an independent 100,000 Genomes cohort." }, { "id": "SCR-LIP-000225", "role": "supporting", "statement": "This review proposes that dysregulated estrogen signaling in adipose tissue—via an increased ERα/ERβ ratio in gluteofemoral adipocytes or excessive local paracrine estrogen production by adipocyte steroidogenic enzymes—drives the excessive subcutaneous fat accumulation in lipedema, and cites whole-exome sequencing linking lipedema to variants in sex hormone genes, with onset coinciding with hormonal fluctuation periods such as puberty, pregnancy, and menopause." }, { "id": "SCR-LIP-000226", "role": "supporting", "statement": "A GWAS of an inferred lipedema phenotype in UK Biobank women identified 18 genome-wide significant loci (SNP heritability ~5.13%), including RSPO3 (OR=1.24), GRB14-COBLL1, VEGFA, and ADAMTS9 (some replicated in an independent clinically-diagnosed lipedema cohort), with genetic correlations to body fat, leptin levels, and age at menopause." }, { "id": "SCR-LIP-000229", "role": "supporting", "statement": "This narrative review reports that lipedema onset is associated with periods of hormonal fluctuation (puberty, pregnancy, menopause) and describes estrogen-dependent mechanisms (increased aromatase CYP19A1, estrogen-induced ZNF423 hyperproliferation), alongside a proposed female-preferential autosomal dominant inheritance pattern." }, { "id": "SCR-LIP-000230", "role": "supporting", "statement": "This review reports that lipedema develops or worsens during hormonal-change windows (puberty, pregnancy, menopause, oral contraceptives), with ~20% of cases identified at menopause and ~67% of patients reporting symptom exacerbation at its onset, and proposes an estrogen-receptor imbalance (decreased ERalpha/increased ERbeta) in affected adipose tissue as a central mechanism." }, { "id": "SCR-LIP-000231", "role": "supporting", "statement": "This review proposes AKR1C enzymes (AKR1C1-4) as a central biological pathway linking rare familial mutations (e.g., AKR1C1 L213Q segregating with lipedema across 3 generations, AKR1C2 Ser320PheTer2) and common regulatory polymorphisms (rs28571848, rs34477787) to lipedema through altered steroid hormone metabolism in gluteofemoral subcutaneous adipose tissue, with environmental endocrine disruptors and hormones converging on the same hereditary pathway." }, { "id": "SCR-LIP-000232", "role": "supporting", "statement": "This review synthesizes evidence that estrogen and its receptors (ERα, ERβ, GPER) influence lipedema pathogenesis, noting disease onset/aggravation during hormonal-fluctuation windows (puberty, pregnancy, menopause) and that altered ER expression in gluteofemoral subcutaneous adipose tissue (reduced ERα, increased ERβ) parallels the regional fat accumulation characteristic of lipedema, affecting ~11% of women." }, { "id": "SCR-LIP-000313", "role": "supporting", "statement": "A scoping review of 25 studies reports that lipedema symptom onset clusters at reproductive hormonal milestones (puberty/adolescence in 62.2-72.0% of cohorts, worsening in pregnancy in 53.0% and menopausal transition in 67.9%), with elevated hormone-sensitive comorbidities (PCOS 12.6-17.1%, autoimmune thyroiditis up to 35.5%) and molecular findings including loss-of-function variants in AKR1C1/AKR1C2, aromatase (CYP19A1) upregulation in adipose tissue, and altered estrogen receptor balance." }, { "id": "SCR-LIP-000314", "role": "supporting", "statement": "This narrative review proposes that lipedema involves a common genetic alteration—an imbalance of estradiol receptors (ERα > ERβ) in adipose tissue present in all cases—combined with physiological hormonal fluctuations (puberty, pregnancy, menopause), endocrine disruptors, and estrogen-dependent gynecological disorders, citing associations such as menstrual irregularities (43%) and PCOS (17%) in women with lipedema." }, { "id": "SCR-LIP-000315", "role": "supporting", "statement": "Whole-exome sequencing in a family with autosomal dominant nonsyndromic primary lipedema identified the AKR1C1 c.638T>A (p.L213Q) variant segregating perfectly with the disease in 3 affected members (puberty onset in all) and absent in 9 unaffected members, with molecular dynamics and QSAR predicting partial loss of 20α-HSD function that may promote lipogenesis via reduced progesterone catabolism." } ], "references": [ "DOI:10.1590/1677-5449.202301832", "DOI:10.7759/cureus.99189", "DOI:10.53347/rid-217362", "DOI:10.1007/s00404-026-08318-1", "DOI:10.1055/a-0767-6842", "DOI:10.1055/a-2183-7414", "DOI:10.1097/prs.0000000000006280", "DOI:10.1016/j.mehy.2014.08.011", "DOI:10.1097/gox.0000000000006173", "DOI:10.3205/iprs000161", "DOI:10.3390/jpm13010098", "DOI:10.1002/ajmg.a.33313", "DOI:10.1111/obr.13953", "DOI:10.3390/ijms26157074", "DOI:10.3390/ijms23126621", "DOI:10.1038/s44324-025-00093-y", "DOI:10.1371/journal.pone.0274867", "DOI:10.1101/2021.06.15.21258988", "DOI:10.3390/ijms222111720", "DOI:10.1038/s41431-022-01231-6", "DOI:10.3390/biomedicines10123081", "DOI:10.3390/endocrines6020024", "DOI:10.4081/vl.2026.15495", "DOI:10.5772/intechopen.96402", "DOI:10.20944/preprints202512.2108.v1", "DOI:10.9734/jammr/2025/v37i25731", "DOI:10.3390/ijms21176264" ], "cite": "Scientific Claim Registry. Do hormonal factors (puberty, pregnancy, menopause, estrogen) trigger or influence lipedema onset?. SQ-LIP-000035 v1.1; 2026-06-02. https://scientificclaims.org/q/SQ-LIP-000035/v1.1.html", "versions": [ { "version": "1.1", "date": "2026-06-02", "url": "https://scientificclaims.org/q/SQ-LIP-000035/v1.1.html" }, { "version": "1.0", "date": "2026-06-02", "url": "https://scientificclaims.org/q/SQ-LIP-000035/v1.0.html" } ], "url": "https://scientificclaims.org/q/SQ-LIP-000035.html", "url_pt": "https://scientificclaims.org/pt/q/SQ-LIP-000035.html", "version_url": "https://scientificclaims.org/q/SQ-LIP-000035/v1.1.html", "license": "CC-BY-4.0", "disclaimer": "Evidence-bounded summary; not medical advice." }